Cargando…

ASCO 2018: highlights of urothelial cancer and prostate cancer

Prostate cancer and urothelial carcinoma are the two most common urological cancers. The aim of this short review is to highlight abstracts from this year’s ASCO Annual Meeting. The phase III SPCG-13 trial showed no difference in biochemical disease-free survival by the addition of docetaxel after p...

Descripción completa

Detalles Bibliográficos
Autores principales: Pichler, Renate, Horninger, Wolfgang, Heidegger, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280775/
https://www.ncbi.nlm.nih.gov/pubmed/30595755
http://dx.doi.org/10.1007/s12254-018-0422-0
_version_ 1783378734952218624
author Pichler, Renate
Horninger, Wolfgang
Heidegger, Isabel
author_facet Pichler, Renate
Horninger, Wolfgang
Heidegger, Isabel
author_sort Pichler, Renate
collection PubMed
description Prostate cancer and urothelial carcinoma are the two most common urological cancers. The aim of this short review is to highlight abstracts from this year’s ASCO Annual Meeting. The phase III SPCG-13 trial showed no difference in biochemical disease-free survival by the addition of docetaxel after primary radiation therapy of localized high-risk prostate cancer. In bone dominant metastatic castration resistant prostate cancer, the phase II radium-223 dose escalation study concluded that the currently used dose with 6 cycles of 55 kBq/kg remains the standard of care. The PARP inhibitor olaparib plus abiraterone provided a significant benefit in radiological progression-free survival compared with abiraterone alone, independent of homologous recombination repair (HRR) mutation status. In localized muscle-invasive urothelial carcinoma, two phase II trials (ABACUS and PURE-01) exploring the pathological complete remission rate of atezolizumab and pembrolizumab prior to cystectomy in cisplatin-unfit or cisplatin-fit patients are presented. Novel targeted therapies such as fibroblast growth factor receptor (FGFR) inhibitors or monoclonal antibodies against nectin-4 confirmed astonishing objective response rates in heavily pretreated metastatic urothelial carcinoma (mUC) patients, resulting in a median overall survival (OS) up to 13.8 months. Finally, updated 1‑year and 2‑year OS survival rates of pembrolizumab and atezolizumab in the first line setting of mUC are presented.
format Online
Article
Text
id pubmed-6280775
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-62807752018-12-26 ASCO 2018: highlights of urothelial cancer and prostate cancer Pichler, Renate Horninger, Wolfgang Heidegger, Isabel Memo Short Review Prostate cancer and urothelial carcinoma are the two most common urological cancers. The aim of this short review is to highlight abstracts from this year’s ASCO Annual Meeting. The phase III SPCG-13 trial showed no difference in biochemical disease-free survival by the addition of docetaxel after primary radiation therapy of localized high-risk prostate cancer. In bone dominant metastatic castration resistant prostate cancer, the phase II radium-223 dose escalation study concluded that the currently used dose with 6 cycles of 55 kBq/kg remains the standard of care. The PARP inhibitor olaparib plus abiraterone provided a significant benefit in radiological progression-free survival compared with abiraterone alone, independent of homologous recombination repair (HRR) mutation status. In localized muscle-invasive urothelial carcinoma, two phase II trials (ABACUS and PURE-01) exploring the pathological complete remission rate of atezolizumab and pembrolizumab prior to cystectomy in cisplatin-unfit or cisplatin-fit patients are presented. Novel targeted therapies such as fibroblast growth factor receptor (FGFR) inhibitors or monoclonal antibodies against nectin-4 confirmed astonishing objective response rates in heavily pretreated metastatic urothelial carcinoma (mUC) patients, resulting in a median overall survival (OS) up to 13.8 months. Finally, updated 1‑year and 2‑year OS survival rates of pembrolizumab and atezolizumab in the first line setting of mUC are presented. Springer Vienna 2018-07-24 2018 /pmc/articles/PMC6280775/ /pubmed/30595755 http://dx.doi.org/10.1007/s12254-018-0422-0 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Short Review
Pichler, Renate
Horninger, Wolfgang
Heidegger, Isabel
ASCO 2018: highlights of urothelial cancer and prostate cancer
title ASCO 2018: highlights of urothelial cancer and prostate cancer
title_full ASCO 2018: highlights of urothelial cancer and prostate cancer
title_fullStr ASCO 2018: highlights of urothelial cancer and prostate cancer
title_full_unstemmed ASCO 2018: highlights of urothelial cancer and prostate cancer
title_short ASCO 2018: highlights of urothelial cancer and prostate cancer
title_sort asco 2018: highlights of urothelial cancer and prostate cancer
topic Short Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280775/
https://www.ncbi.nlm.nih.gov/pubmed/30595755
http://dx.doi.org/10.1007/s12254-018-0422-0
work_keys_str_mv AT pichlerrenate asco2018highlightsofurothelialcancerandprostatecancer
AT horningerwolfgang asco2018highlightsofurothelialcancerandprostatecancer
AT heideggerisabel asco2018highlightsofurothelialcancerandprostatecancer